Alpha-1 Antitrypsin Deficiency Treatment Market Dynamics, Global Insights, Development Analysis, Growth Values and Industry Forecast to 2025

Alpha-1 Antitrypsin Deficiency Treatment Market Overview:

Registering a CAGR of 10.50%, the global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 million in 2018 to USD 2,914.7 million by 2025.
As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.
The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.

Browse Full Report Details and TOC Exclusively @ 
https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319

Alpha-1 Antitrypsin Deficiency Treatment Market-Key Players
·         Kamada Pharmaceuticals
·         CSL Behring LLC
·         Grifols
·         Takeda Pharmaceutical Company Limited
·         GlaxoSmithKline plc
·         Boehringer Ingelheim GmbH
·         AstraZeneca
·         Vectura Group plc
·         Pfizer Inc
·         Mylan Inc
.
Alpha-1 Antitrypsin Deficiency Treatment Market-Segmentation

By Drugs:
·         Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
·         Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
·         Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
·         Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.
By Route of Administration:
·         Oral: The segment is expected to hold the largest market share.
·         Intravenous: The segment is expected to grow at the fastest CAGR.
·         Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
·         Others: Subcutaneous and intramuscular routes of administration.
By Distribution Channel:
·         Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
·         Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
·         Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

By Region
·         Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
·         Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
·         Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.
·         Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more